AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans (Q39194419)

9 September 2017

title

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans (English)

1 reference

9 September 2017

1 reference

Johan Sandin

2

0 references

Per I Arvidsson

object named as

Per I Arvidsson

10

0 references

author name string

Biljana Georgievska

1

1 reference

9 September 2017

James Doherty

3

1 reference

9 September 2017

Anette Mörtberg

4

1 reference

9 September 2017

Jan Neelissen

5

1 reference

9 September 2017

Anita Andersson

6

1 reference

9 September 2017

Susanne Gruber

7

1 reference

9 September 2017

Yvonne Nilsson

8

1 reference

9 September 2017

Pär Schött

9

1 reference

9 September 2017

Sven Hellberg

11

1 reference

9 September 2017

Gunilla Osswald

12

1 reference

9 September 2017

Stefan Berg

13

1 reference

9 September 2017

Johanna Fälting

14

1 reference

9 September 2017

Ratan V Bhat

15

1 reference

9 September 2017

language of work or name

English

0 references

publication date

11 March 2013

1 reference

Journal of Neurochemistry

9 September 2017

published in

1 reference

9 September 2017

volume

125

1 reference

9 September 2017

issue

3

1 reference

9 September 2017

page(s)

446-456

1 reference

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

9 September 2017

cites work

1 reference

NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57Bl/6 mice

21 January 2018

1 reference

Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines

21 January 2018

1 reference

GSK3beta signalling: casting a wide net in Alzheimer's disease

21 January 2018

1 reference

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

21 January 2018

1 reference

Glycogen synthase kinase 3: a drug target for CNS therapies

21 January 2018

1 reference

Synaptic plasticity: multiple forms, functions, and mechanisms

21 January 2018

1 reference

MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampal slices

21 January 2018

1 reference

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices

21 January 2018

1 reference

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase

21 January 2018

1 reference

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments

21 January 2018

1 reference

Glycogen synthase kinase-3 inhibition is integral to long-term potentiation

21 January 2018

1 reference

The GSK3 hypothesis of Alzheimer's disease

21 January 2018

1 reference

Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β.

21 January 2018

1 reference

GSK3 and Alzheimer's Disease: Facts and Fiction….

21 January 2018

1 reference

Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder.

21 January 2018

1 reference

Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.

21 January 2018

1 reference

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

21 January 2018

1 reference

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease

21 January 2018

1 reference

Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes

21 January 2018

1 reference

LTP inhibits LTD in the hippocampus via regulation of GSK3beta

21 January 2018

1 reference

The role of GSK-3 in synaptic plasticity.

21 January 2018

1 reference

A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases

21 January 2018

1 reference

21 January 2018

1 reference

Distribution of tau protein kinase I/glycogen synthase kinase-3beta, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain.

21 January 2018

1 reference

cDNA cloning and properties of glycogen synthase kinase-3.

21 January 2018

1 reference

Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JNC.12203

1 reference

9 September 2017

1 reference